SAN DIEGO, Feb. 22, 2011 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (OTCBB:HRBR), which is investigating the use the company's proprietary compound Triolex® as a treatment for Parkinson's disease (PD) with funding from The Michael J. Fox
SAN DIEGO, Feb. 7, 2011 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (OTCBB:HRBR), a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical
NEW YORK, Oct. 20, 2010 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Harbor BioSciences, Inc. Harbor BioSciences, Inc.'s stock was suspended on September 23, 2010 and has not traded on NASDAQ
SAN DIEGO, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and
SAN DIEGO, Sept. 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) received notification from NASDAQ that it has not complied with NASDAQ Listing Rule 5550(a)(2) and, unless the Company appeals, trading of the Company's common stock
Harbor BioSciences Inc. shares surged Wednesday after reporting positive data from an early-stage clinical trial for its experimental prostate cancer treatment Apoptone. Harbor shares rose 32% to 31 cents in recent activity. Among the data,...
Shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) surged as much as 23% after it announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.